Global Paediatric Drug Development Centre of Excellence opened in Dublin’s North Dock

pharmafile | April 7, 2022 | News story | Business Services  

Gilead Sciences announced on April 6th the formal opening of its Dublin city centre office, focused on developing new paediatric formulations for its portfolio of medicines. Development, clinical operations, legal/IP, medical affairs, and regulatory teams will work together to create the company’s only Global Paediatric Centre of Excellence.

IDA Ireland CEO Martin Shanahan shared: “IDA Ireland welcomes Gilead’s expansion of its Irish operations, establishing in Dublin this global biotechnology company’s first Global Centre of Excellence for Paediatric Clinical Trials outside of the US. It’s a strong vote of confidence in Ireland for investment of this kind and will be a welcome addition to the growing biotech ecosystem here.”

The centre will be based in the North Dock of the city centre.

An Taoiseach – the prime minister and head of government of Ireland – Micheál Martin said: “I am delighted to join with Gilead Sciences to mark the opening of their new Centre of Excellence for Paediatric Drug Development in the Dublin Docklands and the creation of 33 new jobs – a very welcome and positive announcement for the city. Gilead Sciences is a great example of a business delivering on the global stage, supported by our accomplished and skilled workforce.

“After over 20 years here in Ireland, this will be Gilead’s fourth facility here, further underlining the leading role this country plays in the company’s operations in Europe. Gilead’s drive and commitment to innovation, and to the highest standards of pharmaceutical technology, is clear to see, and will, I’m sure, continue to bring the company considerable further success in the years ahead.”

Gilead is a global biopharmaceutical company aiming to create a healthier world with a focus on life-threatening diseases, including cancer.

“Gilead’s therapies address some of the world’s most challenging viral diseases, including HIV, viral hepatitis and COVID-19. Our Dublin teams play a critical role in adapting these therapies to treat children. In addition, as Gilead expands its work in oncology, our Irish teams could help to address the urgent challenge of childhood cancers,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “Ireland has long been a global hub for life sciences and Gilead is proud to have been part of that since 1999. The new Dublin facility is a further investment in our long-term presence.”

Ana Ovey

Related Content

No items found

Latest content